Are taxanes the future for head and neck cancer? Pragmatism in the immunotherapy era

Michael Hwang; Tanguy Y. Seiwert

doi:10.1016/S1470-2045(21)00121-2

Are taxanes the future for head and neck cancer? Pragmatism in the immunotherapy era

Michael Hwang, Tanguy Y. Seiwert

School of Medicine

Research output: Contribution to journal › Comment/debate › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	413-415
Number of pages	3
Journal	The Lancet Oncology
Volume	22
Issue number	4
DOIs	https://doi.org/10.1016/S1470-2045(21)00121-2
State	Published - Apr 2021

ASJC Scopus subject areas

Oncology

Access to Document

10.1016/S1470-2045(21)00121-2

Cite this

@article{405a7b5db0d8414b8e4e11e5f2d4498f,

title = "Are taxanes the future for head and neck cancer? Pragmatism in the immunotherapy era",

author = "Michael Hwang and Seiwert, {Tanguy Y.}",

note = "Funding Information: TYS has received honoraria and institutional grants from Merck, Nanobiotix, Regeneron, and AstraZeneca; honoraria from Innate Pharma, eTheRNA, and Nektar; and an institutional grant from Bristol Myers Squibb, all outside the submitted work. MH declares no competing interests.",

year = "2021",

month = apr,

doi = "10.1016/S1470-2045(21)00121-2",

language = "English (US)",

volume = "22",

pages = "413--415",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "4",

}

TY - JOUR

T1 - Are taxanes the future for head and neck cancer? Pragmatism in the immunotherapy era

AU - Hwang, Michael

AU - Seiwert, Tanguy Y.

N1 - Funding Information: TYS has received honoraria and institutional grants from Merck, Nanobiotix, Regeneron, and AstraZeneca; honoraria from Innate Pharma, eTheRNA, and Nektar; and an institutional grant from Bristol Myers Squibb, all outside the submitted work. MH declares no competing interests.

PY - 2021/4

Y1 - 2021/4

UR - http://www.scopus.com/inward/record.url?scp=85103335878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85103335878&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(21)00121-2

DO - 10.1016/S1470-2045(21)00121-2

M3 - Comment/debate

C2 - 33684371

AN - SCOPUS:85103335878

SN - 1470-2045

VL - 22

SP - 413

EP - 415

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 4

ER -

Are taxanes the future for head and neck cancer? Pragmatism in the immunotherapy era

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this